WEKO3
アイテム
{"_buckets": {"deposit": "f8da8851-2183-4bac-bcd5-5519ef6705a9"}, "_deposit": {"created_by": 27, "id": "15823", "owners": [27], "pid": {"revision_id": 0, "type": "depid", "value": "15823"}, "status": "published"}, "_oai": {"id": "oai:toyama.repo.nii.ac.jp:00015823", "sets": ["442"]}, "author_link": ["168042", "168048", "168045", "168049", "5960", "168052", "5946", "168047", "41305", "168050", "168044", "168046", "168051", "5948"], "item_2_biblio_info_7": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2016-05", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "5", "bibliographicPageEnd": "778", "bibliographicPageStart": "774", "bibliographicVolumeNumber": "4", "bibliographic_titles": [{}, {"bibliographic_title": "Molecular and clinical oncology", "bibliographic_titleLang": "en"}]}]}, "item_2_description_15": {"attribute_name": "フォーマット", "attribute_value_mlt": [{"subitem_description": "application/pdf", "subitem_description_type": "Other"}]}, "item_2_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Treatment with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) has been shown to prolong survival in patients with EGFR mutation-positive non-small cell lung cancer (NSCLC). The present study performed a retrospective analysis to investigate the association between the plasma lactate dehydrogenase (LDH) levels and survival in patients with EGFR mutation-positive NSCLC receiving treatment with EGFR-TKIs. The medical charts of patients with EGFR mutation-positive NSCLC who were receiving treatment with EGFR-TKIs at Toyama University Hospital between 2007 and 2014 were assessed. The data from 65 patients were included in the analysis. Patients with higher plasma LDH levels exhibited shorter progression-free survival (6.2 vs. 13.2 months; P\u003c0.01) and overall survival (10.5 vs. 36.1 months; P\u003c0.01) periods compared with patients with lower plasma LDH levels. A Cox proportional hazards model identified that the plasma LDH level was associated with the progression-free survival (P=0.05) and overall survival (P\u003c0.01). An association was demonstrated between the pretreatment plasma LDH level and the survival in patients with EGFR mutation-positive NSCLC receiving treatment with EGFR-TKIs. Close observation is required in EGFR mutation-positive NSCLC patients exhibiting high plasma LDH levels following the initiation of treatment with EGFR-TKIs.", "subitem_description_type": "Abstract"}]}, "item_2_description_40": {"attribute_name": "資源タイプ(DSpace)", "attribute_value_mlt": [{"subitem_description": "Article", "subitem_description_type": "Other"}]}, "item_2_description_5": {"attribute_name": "内容記述", "attribute_value_mlt": [{"subitem_description": "出版社サイトへのリンク:https://doi.org/10.3892/mco.2016.779", "subitem_description_type": "Other"}]}, "item_2_description_6": {"attribute_name": "引用", "attribute_value_mlt": [{"subitem_description": "Mol Clin Oncol. 2016 May;4(5):774-778. ", "subitem_description_type": "Other"}]}, "item_2_publisher_33": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Spandidos Publications"}]}, "item_2_relation_11": {"attribute_name": "PubMed番号", "attribute_value_mlt": [{"subitem_relation_type": "isIdenticalTo", "subitem_relation_type_id": {"subitem_relation_type_id_text": "27123277", "subitem_relation_type_select": "PMID"}}]}, "item_2_relation_12": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isIdenticalTo", "subitem_relation_type_id": {"subitem_relation_type_id_text": "info:doi/10.3892/mco.2016.779", "subitem_relation_type_select": "DOI"}}]}, "item_2_source_id_8": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "2049-9450", "subitem_source_identifier_type": "ISSN"}]}, "item_2_version_type_16": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Inomata, Minehiko"}], "nameIdentifiers": [{"nameIdentifier": "168042", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hayashi, Ryuji"}], "nameIdentifiers": [{"nameIdentifier": "5946", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "9000003761101", "nameIdentifierScheme": "CiNii ID", "nameIdentifierURI": "http://ci.nii.ac.jp/nrid/9000003761101"}, {"nameIdentifier": "60345585", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://nrid.nii.ac.jp/nrid/1000060345585"}]}, {"creatorNames": [{"creatorName": "Tanaka, Hiroaki"}], "nameIdentifiers": [{"nameIdentifier": "168044", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Shimokawa, Kazuki"}], "nameIdentifiers": [{"nameIdentifier": "168045", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tokui, Kotaro"}], "nameIdentifiers": [{"nameIdentifier": "168046", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Taka, Chihiro"}], "nameIdentifiers": [{"nameIdentifier": "168047", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Okazawa, Seisuke"}], "nameIdentifiers": [{"nameIdentifier": "168048", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kambara, Kenta"}], "nameIdentifiers": [{"nameIdentifier": "168049", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ichikawa, Tomomi"}], "nameIdentifiers": [{"nameIdentifier": "168050", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yamada, Toru"}], "nameIdentifiers": [{"nameIdentifier": "168051", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Miwa, Toshiro"}], "nameIdentifiers": [{"nameIdentifier": "168052", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kashii, Tatsuhiko"}], "nameIdentifiers": [{"nameIdentifier": "5960", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "9000003745259", "nameIdentifierScheme": "CiNii ID", "nameIdentifierURI": "http://ci.nii.ac.jp/nrid/9000003745259"}, {"nameIdentifier": "00313619", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://nrid.nii.ac.jp/nrid/1000000313619"}]}, {"creatorNames": [{"creatorName": "Matsui, Shoko"}], "nameIdentifiers": [{"nameIdentifier": "5948", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "9000002258842", "nameIdentifierScheme": "CiNii ID", "nameIdentifierURI": "http://ci.nii.ac.jp/nrid/9000002258842"}, {"nameIdentifier": "40334726", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://nrid.nii.ac.jp/nrid/1000040334726"}]}, {"creatorNames": [{"creatorName": "Tobe, Kazuyuki"}], "nameIdentifiers": [{"nameIdentifier": "41305", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "9000006696254", "nameIdentifierScheme": "CiNii ID", "nameIdentifierURI": "http://ci.nii.ac.jp/nrid/9000006696254"}, {"nameIdentifier": "30251242", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://nrid.nii.ac.jp/nrid/1000030251242"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2018-03-07"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "MolClinOnclo_4(5)_774to778_Inomata.pdf", "filesize": [{"value": "361.9 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 361900.0, "url": {"label": "MolClinOnclo_4(5)_774to778_Inomata", "url": "https://toyama.repo.nii.ac.jp/record/15823/files/MolClinOnclo_4(5)_774to778_Inomata.pdf"}, "version_id": "fc74a108-a03e-4beb-9d79-a2a5465bb60f"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Elevated levels of plasma lactate dehydrogenase is an unfavorable prognostic factor in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer, receiving treatment with gefitinib or erlotinib.", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Elevated levels of plasma lactate dehydrogenase is an unfavorable prognostic factor in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer, receiving treatment with gefitinib or erlotinib."}, {"subitem_title": "Elevated levels of plasma lactate dehydrogenase is an unfavorable prognostic factor in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer, receiving treatment with gefitinib or erlotinib.", "subitem_title_language": "en"}]}, "item_type_id": "2", "owner": "27", "path": ["442"], "permalink_uri": "http://hdl.handle.net/10110/00018287", "pubdate": {"attribute_name": "公開日", "attribute_value": "2018-03-07"}, "publish_date": "2018-03-07", "publish_status": "0", "recid": "15823", "relation": {}, "relation_version_is_last": true, "title": ["Elevated levels of plasma lactate dehydrogenase is an unfavorable prognostic factor in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer, receiving treatment with gefitinib or erlotinib."], "weko_shared_id": 27}
Elevated levels of plasma lactate dehydrogenase is an unfavorable prognostic factor in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer, receiving treatment with gefitinib or erlotinib.
http://hdl.handle.net/10110/00018287
http://hdl.handle.net/10110/000182876d809469-29d2-49cd-8a2e-1479d398daee
名前 / ファイル | ライセンス | アクション |
---|---|---|
MolClinOnclo_4(5)_774to778_Inomata (361.9 kB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2018-03-07 | |||||
タイトル | ||||||
タイトル | Elevated levels of plasma lactate dehydrogenase is an unfavorable prognostic factor in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer, receiving treatment with gefitinib or erlotinib. | |||||
タイトル | ||||||
言語 | en | |||||
タイトル | Elevated levels of plasma lactate dehydrogenase is an unfavorable prognostic factor in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer, receiving treatment with gefitinib or erlotinib. | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
Inomata, Minehiko
× Inomata, Minehiko× Hayashi, Ryuji× Tanaka, Hiroaki× Shimokawa, Kazuki× Tokui, Kotaro× Taka, Chihiro× Okazawa, Seisuke× Kambara, Kenta× Ichikawa, Tomomi× Yamada, Toru× Miwa, Toshiro× Kashii, Tatsuhiko× Matsui, Shoko× Tobe, Kazuyuki |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Treatment with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) has been shown to prolong survival in patients with EGFR mutation-positive non-small cell lung cancer (NSCLC). The present study performed a retrospective analysis to investigate the association between the plasma lactate dehydrogenase (LDH) levels and survival in patients with EGFR mutation-positive NSCLC receiving treatment with EGFR-TKIs. The medical charts of patients with EGFR mutation-positive NSCLC who were receiving treatment with EGFR-TKIs at Toyama University Hospital between 2007 and 2014 were assessed. The data from 65 patients were included in the analysis. Patients with higher plasma LDH levels exhibited shorter progression-free survival (6.2 vs. 13.2 months; P<0.01) and overall survival (10.5 vs. 36.1 months; P<0.01) periods compared with patients with lower plasma LDH levels. A Cox proportional hazards model identified that the plasma LDH level was associated with the progression-free survival (P=0.05) and overall survival (P<0.01). An association was demonstrated between the pretreatment plasma LDH level and the survival in patients with EGFR mutation-positive NSCLC receiving treatment with EGFR-TKIs. Close observation is required in EGFR mutation-positive NSCLC patients exhibiting high plasma LDH levels following the initiation of treatment with EGFR-TKIs. | |||||
内容記述 | ||||||
内容記述タイプ | Other | |||||
内容記述 | 出版社サイトへのリンク:https://doi.org/10.3892/mco.2016.779 | |||||
引用 | ||||||
内容記述タイプ | Other | |||||
内容記述 | Mol Clin Oncol. 2016 May;4(5):774-778. | |||||
書誌情報 |
en : Molecular and clinical oncology 巻 4, 号 5, p. 774-778, 発行日 2016-05 |
|||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 2049-9450 | |||||
PubMed番号 | ||||||
関連タイプ | isIdenticalTo | |||||
識別子タイプ | PMID | |||||
関連識別子 | 27123277 | |||||
DOI | ||||||
関連タイプ | isIdenticalTo | |||||
識別子タイプ | DOI | |||||
関連識別子 | info:doi/10.3892/mco.2016.779 | |||||
フォーマット | ||||||
内容記述タイプ | Other | |||||
内容記述 | application/pdf | |||||
著者版フラグ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
出版者 | ||||||
出版者 | Spandidos Publications | |||||
資源タイプ(DSpace) | ||||||
内容記述タイプ | Other | |||||
内容記述 | Article |